NaDeNo develops a nanotechnology drug delivery platform utilizing biodegradable and biocompatible polymeric nanoparticles to encapsulate hydrophobic small molecule drugs, addressing the challenge of low water solubility that leads to high failure rates in drug development. The platform enables controlled drug release and improved efficacy, facilitating the repurposing of effective drugs for areas with significant unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Many small molecule drugs exhibit poor water solubility, leading to formulation challenges and high failure rates during drug development. This limits the therapeutic potential of otherwise effective drugs, particularly in areas with significant unmet medical needs.
Solution
NaDeNo is developing a nanotechnology drug delivery platform based on biodegradable and biocompatible polymeric nanoparticles designed to encapsulate hydrophobic small molecule drugs. This platform overcomes drug delivery hurdles by improving drug solubility, controlling drug release, and enhancing efficacy. The nanoparticles can be tailored for specific applications and routes of administration, with the potential for active targeting. NaDeNo's technology aims to repurpose effective drugs by improving their delivery and reducing toxicity.
Target Audience
NaDeNo's primary customers are pharmaceutical and biotechnology companies seeking advanced drug delivery solutions for hydrophobic small molecule drugs.
Features
- Biodegradable and biocompatible polymeric nanoparticles for drug encapsulation
- High drug loading capacity for hydrophobic small molecule drugs
- Controlled drug release profiles
- Surface modification for targeted drug delivery
- Simple and scalable manufacturing process
- Demonstrated superior efficacy and low systemic toxicity in preclinical mouse cancer models
- Long shelf stability and colloidal stability in biological fluids